Caprion Pharmaceuticals Inc has made Canadian biotechnology history, attracting the largest private placement to date with a $52.5-million investment by venture capital and institutional investors. The Montreal-based proteomics company has now raised $64 million in capital and will use the funds to conduct research for diagnostic compounds and therapeutics products combining sub-cellular biology and large-scale mass spectrometry.